Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Christine Brown
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mustang Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Mustang Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancer centers, as well as lentiviral gene therapy for X-SCID. Dr. Brown serves as an advisory board member for Mustang. Dr. Brown is a Co-Principal Investigator on the funded research grant that proposes to replace the single chain variable fragment (scFv) domain with either a fragment or antigen-binding domain (Fab) or a monoclonal antibody (mAb) that is engineered to bind to a cyclic peptide called meditope. Given that the business priorities of Mustang were determined to be similar to the aims of the grant, Dr. Brown's SFI was determined to be related to the research.
In situ Imaging of CAR T-cells
The objective of this application is to exploit our recent discovery and development of a unique, high affinity binding site within a monoclonal antibody (mAb) as a means to add novel functionality to chimeric antigen receptor (CAR) T cell therapies. Specifically, we will generate, characterize, and demonstrate that we can effectively replace an anti-Her2 scFv with an anti-Her2 meditope-enabled Fab or meditope-enabled mAb and to use this site for imaging CAR T cells in vivo. Successful demonstration of this technology will open up new avenues to improve adoptive immunotherapy, a highly promising and emerging treatment applicable to multiple forms of cancer.
Filed on September 17, 2018.
Tell us what you know about Christine Brown's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Christine Brown filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Christine Brown | Beckman Research Institute/city of Hope | Conflict of Interest | Mustang Bio., Inc. | $300,000 - $349,999 |
| Christine Brown | Beckman Research Institute/city of Hope | Conflict of Interest | Mustang Bio., Inc. | $80,000 - $99,999 |
| Christine Brown | Beckman Research Institute/city of Hope | Conflict of Interest | Mustang Bio., Inc. | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.